Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of progestational hormone in preparing glycogen synthase kinase-3beta inhibitor medicine, and glycogen synthase kinase-3beta inhibitor

A technology for glycogen synthesis and progesterone, which is applied in the field of biomedicine, can solve problems such as complex composition, difficult popularization, cumbersome preparation methods, etc., and achieve the effect of increasing expression and good inhibitory effect

Pending Publication Date: 2018-07-13
SHENZHEN EVERGREEN THERAPEUTICS CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the development and research of Glycogen Synthase Kinase-3 inhibitors is very important, but the Glycogen Synthase Kinase-3 inhibitors in the prior art have complex compositions, complicated preparation methods, and are not easy to popularize

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of progestational hormone in preparing glycogen synthase kinase-3beta inhibitor medicine, and glycogen synthase kinase-3beta inhibitor
  • Application of progestational hormone in preparing glycogen synthase kinase-3beta inhibitor medicine, and glycogen synthase kinase-3beta inhibitor
  • Application of progestational hormone in preparing glycogen synthase kinase-3beta inhibitor medicine, and glycogen synthase kinase-3beta inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. Preparation of PR2005

[0031] Dissolve progesterone / 17α-hydroxyprogesterone caproate in 1% DMSO solvent, vibrate for 5 minutes, and freshly prepare small-dose PR2005: 0.03mg / L, medium-dose PR2005: 0.15mg / L, and large-dose PR2005: 0.3mg / L solution.

Embodiment 2

[0032] Embodiment 2. making animal model

[0033] Seventy healthy and clean male C57 / BL6 mice aged 10 weeks were selected. The animals were acclimated to the environment for one week before the experiment. They were randomly divided into experimental group and control group according to the method shown in the figure below, and the chronic COPD model was established in the experimental group according to the following method.

[0034] The specific method of establishing a chronic COPD model: All mice inhale 2.5ppm O3 in a special O3 inhalation container for 3 hours, twice a week, for 6 weeks. After 6 weeks, continue to inhale O3 according to this method, and the experimental group is randomly divided into Normal saline (NS) nebulization group, Budesonide (BUD) nebulization group, low-dose PR2005 treatment group, high-dose PR2005 treatment group, desonide + low-dose PR2005 treatment group, desonide + medium-dose PR2005 treatment group group, budesonide + high-dose PR2005 treat...

Embodiment 3

[0037] Example 3. Examination of bronchoalveolar lavage fluid

[0038] Use 0.4ml, 0.4ml, 0.4ml of sterile saline at 4°C to lavage the endotracheal tube three times, and the recovery rate is greater than 80% as a qualified specimen. After centrifugation at 1500r / min for 10min, the supernatant was taken out and stored at -80°C. The supernatant was detected by ELISA method for matrix metalloproteinase-8 (MMP-8), MMP-9 and other cytokines.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of progestational hormone in preparing a glycogen synthase kinase-3beta (GSK-3beta) inhibitor medicine, and a glycogen synthase kinase-3beta (GSK-3beta) inhibitor,and belongs to the field of medicines. The invention discloses the application of the progestational hormone as an active ingredient in preparing the glycogen synthase kinase-3beta (GSK-3beta) inhibitor medicine; the progestational hormone is selected from one or several of 17alpha-hydroxyprogesterone caproate (17-HPC), medroxyprogesterone (MPA) or natural progesterone (P4). The glycogen synthasekinase-3beta (GSK-3beta) inhibitor taking the progestational hormone as the active ingredient, provided by the invention, is simple in composition, a preparation method is simplified, and the progestational hormone is easy to popularize and promote.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of progesterone as an active ingredient in the preparation of glycogen synthase kinase-3β (GSK-3β) inhibitor drugs. Background technique [0002] GSK-3β is an important signaling protein that has been shown to regulate a wide range of cellular functions, including apoptosis and cell proliferation. Dysregulation of GSK-3β has been implicated in a wide range of human diseases, including schizophrenia, type 2 diabetes (Type 2 diabetes), Alzheimer's disease, inflammation, kidney disease, cancer and bipolar disorder. [0003] Tumor occurrence is a complex pathological process, affected by multiple factors, including individual genetic factors, environmental factors, physical and chemical factors, molecular biological factors and so on. With the rapid development of life sciences and the in-depth development of molecular biology research on the pathogenic mechanism and patho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/57A61K31/58A61P11/00
CPCA61K31/57A61K31/58A61K2300/00
Inventor 杜涛
Owner SHENZHEN EVERGREEN THERAPEUTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com